ArticleACS applied materials & interfaces2022
Enhanced Label-Free Nanoplasmonic Cytokine Detection in SARS-CoV-2 Induced Inflammation Using Rationally Designed Peptide Aptamer.
Article in ACS applied materials & interfaces, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Peptide Aptamers: Innovative Design and Applications in Pathogen Detection.Chembiochem : a European journal of chemical biology · 2026Review
- BRICHOS-Biased Inhibition Contributes to Aβ42 Dominance in Parenchymal Plaques Despite Higher Aβ40 Abundance and Coaggregation Capability.Biomacromolecules · 2026Article
- Peptide Aptamer-Enabled Nanoplasmonic Digital Immunoassay for Ultrasensitive Cytokine Sensing in Early Inflammation and Immune Modulation.ACS sensors · 2026Article
- Development of a Miniaturized, Automated, and Cost-Effective Device for Enzyme-Linked Immunosorbent Assay.Sensors (Basel, Switzerland) · 2025Article
- Sustainable Integration of Nanobiosensors in Biomedical and Civil Engineering: A Comprehensive Review.ACS omega · 2025Review
- A nanoplasmonic cell-on-a-chip for in situ monitoring of PD-L1Biosensors & bioelectronics · 2025Article
- Impact of frequent ARID1A mutations on protein stability provides insights into cancer pathogenesis.Scientific reports · 2025Article
- Impact of Frequent ARID1A Mutations on Protein Stability: Insights into Cancer Pathogenesis.Research square · 2024Article
- Scanning Probe Nano-Infrared Imaging and Spectroscopy of Biochemical and Natural Materials.Small science · 2024Article
- Synthesis and characterization of core-shell magnetic molecularly imprinted polymer nanocomposites for the detection of interleukin-6.Analytical and bioanalytical chemistry · 2024Article
- Recent Progresses in Optical Biosensors for Interleukin 6 Detection.Biosensors · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
Rapid and precise serum cytokine quantification provides immense clinical significance in monitoring the immune status of patients in rapidly evolving infectious/inflammatory disorders, examplified by the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. However, real-time information on predictive cytokine biomarkers to guide targetable immune pathways in pathogenic inflammation is critically lacking, because of the insufficient detection range and detection limit in current label-free cytokine immunoassays. In this work, we report a highly sensitive localized surface plasmon resonance imaging (LSPRi) immunoassay for label-free Interleukin 6 (IL-6) detection utilizing rationally designed peptide aptamers as the capture interface. Benefiting from its characteristically smaller dimension and direct functionalization on the sensing surface via Au-S bonding, the peptide-aptamer-based LSPRi immunoassay achieved enhanced label-free serum IL-6 detection with a record-breaking limit of detection down to 4.6 pg/mL, and a wide dynamic range of ∼6 orders of magnitude (values from 4.6 to 1 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.